Who
Jim Wassil
EVP, Chief Scientific Ofc, COO
Company insider
Files Form 4 as: EVP, Chief Scientific Ofc, COO, Vaxcyte; Director and Other, Icosavax.
In numbers
- Trades disclosed
- 245
- Buys
- 0
- Sells
- 39
- Bought
- $0
- Sold
- $14.3M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 20 Jan 2021
- Last trade
- 5 Oct 2026
- Last filed
- 7 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Oct 2026filed 7 Oct 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code M | $96K18,000 at $5.35 | filing |
| 5 Oct 2026filed 7 Oct 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $1.6M18,000 at $86.74 | filing |
| 5 Oct 2026filed 7 Oct 2026 | PCVX Vaxcyteoption or derivative · Biotechnology | SEC FORM 4 Code M | —18,000 at $0.00 | filing |
| 1 Oct 2026filed 2 Oct 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code M | $12K2,250 at $5.35 | filing |
| 1 Oct 2026filed 2 Oct 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $122K2,155 at $56.65 | filing |
| 1 Oct 2026filed 2 Oct 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $5,42495 at $57.09 | filing |
| 1 Oct 2026filed 2 Oct 2026 | PCVX Vaxcyteoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,250 at $0.00 | filing |
| 9 Sep 2026filed 9 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $79K1,334 at $59.52 | filing |
| 9 Sep 2026filed 9 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $79K1,334 at $59.52 | filing |
| 8 Sep 2026filed 9 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code F | $330K5,459 at $60.36 | filing |
| 8 Sep 2026filed 9 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code F | $330K5,459 at $60.36 | filing |
| 4 Sep 2026filed 9 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $84K1,381 at $61.16 | filing |
| 4 Sep 2026filed 9 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $84K1,381 at $61.16 | filing |
| 2 Sep 2026filed 2 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code F | $88K1,432 at $61.58 | filing |
| 2 Sep 2026filed 2 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code F | $88K1,432 at $61.58 | filing |
| 1 Sep 2026filed 2 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code M | $12K2,250 at $5.35 | filing |
| 1 Sep 2026filed 2 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $94K1,537 at $60.89 | filing |
| 1 Sep 2026filed 2 Sep 2026 | PCVX Vaxcyteoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,250 at $0.00 | filing |
| 1 Sep 2026filed 2 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $44K713 at $61.48 | filing |
| 1 Sep 2026filed 2 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $56K924 at $60.96 | filing |
News
Vaxcyte (NASDAQ:PCVX) Stock: Insider Jim Wassil Sells 2,250 Sharestickerreport.com · 2 Oct 2026Jim Wassil Sells 1,381 Shares of Vaxcyte (NASDAQ:PCVX) Stockthemarketsdaily.com · 10 Sep 2026Show Me The Money: Vaxcyte Delivers 100%+ Gains As Pneumococcal Vaccine Program AdvancesPCVX · rttnews.com · 16 Oct 2026Vaxcyte's (PCVX) Overweight Rating Reaffirmed at Cantor FitzgeraldPCVX · dailypolitical.com · 13 Oct 2026
2 headlines in the last 90 days name Jim Wassil; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.